Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of apatinib in preparation of medicine for preventing and treating NLRP3 inflammasome related diseases

A technology of inflammasome and apatinib, applied in the field of medicine, can solve problems such as deficiency, and achieve the effect of inhibiting maturation and secretion, and inhibiting the activation of NLRP3 inflammasome

Inactive Publication Date: 2021-08-10
GUANGZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many inhibitors have a certain alleviation effect on NLRP3 inflammasome-related diseases in basic research, there is still a lack of drugs that inhibit the activation of NLRP3 inflammasome in clinical practice.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of apatinib in preparation of medicine for preventing and treating NLRP3 inflammasome related diseases
  • Application of apatinib in preparation of medicine for preventing and treating NLRP3 inflammasome related diseases
  • Application of apatinib in preparation of medicine for preventing and treating NLRP3 inflammasome related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Enzyme-linked immunosorbent assay Apatinib inhibits the release of IL-1β activated by NLRP3 inflammasome

[0051] 1. On the first day, divide J774A.1 cells into 96-well plate, each well 5×10 5 cells;

[0052] 2. Seed the plate overnight, discard the supernatant, add 100 μL of DMEM medium containing 10% serum containing bacterial lipopolysaccharide (LPS) (1 μg / ml) to each well, and then add different concentrations of (0 μM, 0.25 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM) apatinib treatment for 1 hour, and then add nigericin (Nigericin, 10 μM) for 1 hour;

[0053] 3. After the treatment in step 2, collect the cell supernatant, and use the Mouse IL-1β ELISA kit to measure the IL-1β content. The operation steps are carried out according to the kit instructions, and the inhibition percentage for inhibiting the release of IL-1β is calculated. See the results in figure 1 and figure 2 .

[0054] figure 1 and figure 2 The results showed that under the joint...

Embodiment 2

[0055] Example 2 Determination of Apatinib Inhibition of NLRP3 Inflammasome Activation by Western Blot

[0056] (1) On the first day, J774A.1 cells were inoculated into cell culture dishes with a diameter of 35mm, and each dish contained 5×10 6 cells;

[0057] (2) After 12 hours of cell growth and proliferation in the cell culture dish, the supernatant was discarded, and 1 ml of DMEM medium containing 10% serum containing bacterial lipopolysaccharide (1ug / ml) was added to each dish for 5 hours, and then different concentrations (0μM , 0.25 μM, 0.5 μM) of apatinib for 1 hour, and then add nigericin (Nigericin, 10uM) for 1 hour;

[0058] (3) After the treatment in step (2), collect the cell supernatant and cell lysate, extract the supernatant protein and cell lysate protein from the supernatant and lysate according to the conventional method, and use anti-IL-1β antibody, anti-Caspase-1 antibody , anti-NLRP3 antibody and anti-ASC antibody for Western blotting analysis, see the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of apatinib in preparation of a medicine for preventing and / or treating NLRP3 inflammasome related diseases. The apatinib can be used for effectively inhibiting the activation of the NLRP3 inflammasome and inhibiting the maturation and secretion of an inflammatory cytokine IL-1beta so that the apatinib has a great value in the development of medicines for preventing and / or treating NLRP3 inflammasome related diseases.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of apatinib in the preparation of medicines for preventing and treating diseases related to NLRP3 inflammasomes. Background technique [0002] NLRP3 inflammasome is a pattern recognition receptor (PRR) and an inflammatory activation platform of Caspase-1. It can recognize exogenous pathogen-associated molecular pattern (PAMP) such as lipopolysaccharide LPS, viral RNA or endogenous damage-associated molecular pattern (DAMP) such as DNA, endotoxin , uric acid, ATP, Aβ and cell debris, etc. Abnormal appearance of these substances in a certain part outside the cell or inside the cell stimulates the homeostasis of the tissue and activates the NLRP3 inflammasome, resisting damage to the body by exogenous or endogenous factors, but excessively activated NLRP3 inflammation The small body can lead to the development of many diseases. A large number of literatures have proved tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/444A61P29/00A61P43/00
CPCA61K31/444A61P29/00A61P43/00
Inventor 熊兮陈秀会胡文辉
Owner GUANGZHOU MEDICAL UNIV